📌 At a glance:
- FY25 PAT: ₹566 crore (–15% YoY)
- FY25 Revenue: ₹2,479 crore (–2.6%)
- Q4 PAT: ₹126 crore (–21% YoY)
- CMP: ₹4,890.00 (+9.44% today)
🧬 About the Company
Pfizer Ltd is the Indian arm of the global pharma giant. It operates primarily in branded formulations including vaccines, anti-infectives, pain management, and cardiology. Unlike its global parent, it doesn’t manufacture the COVID vaccine in India.
👨⚕️ KMP
- MD: Meenakshi Nevatia
📊 FY25 Financial Summary
| Metric | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Revenue | ₹2,479 cr | ₹2,545 cr | –2.6% |
| PAT | ₹566 cr | ₹665 cr | –15% |
| Q4 PAT | ₹126 cr | ₹160 cr | –21% |
🩺 What’s Going On?
- Revenue drop driven by lower sales in anti-infectives and women’s health
- Margin compression due to increased raw material cost
- Focus shifting to chronic and lifestyle therapies
🧮 Fair Value Estimate
- FY27E PAT = ₹720 cr (8% CAGR)
- P/E = 30x (premium MNC pharma valuation)
- MCap = ₹21,600 cr → FV/share ≈ ₹4,035 (≈5.35 cr shares)
- CMP = ₹4,890 → Expensive zone
⚠️ Risks
- Limited product launches in India
- Import dependence for APIs and formulations
- MNC royalty outflows impact bottom-line
💡 Positives
- Debt-free, cash-rich balance sheet
- High return ratios (ROCE > 25%)
- Strong brand equity across prescription space
😂 EduInvesting Take
- ₹566 cr profit for a ₹26,000 cr company? That’s like showing up to a party with Diet Coke.
- The stock soared 9% today… but valuations are floating like an overinflated hospital bill
- Verdict: “Great brand, great balance sheet — but not a great price.”
P.S.: Dividend lovers may still want to nibble.
